Skip to content

Study · Non-randomized trial · n = 9 · 2009

8 results

Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used.

King AB

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Apr 2009Cited by 10 (Europe PMC)

PMID19364691 (opens in a new tab)DOI10.4158/ep.15.3.229 (opens in a new tab)PepBankPUB-19364691
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In patients with type 1 diabetes, hypoglycemia occurred in 6 patients without requiring another person's assistance.

    In plain wordsIn patients with type 1 diabetes, 6 patients had low blood sugar without needing another person's help.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableHypoglycemia
    Study

    n = 9

    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Titrated to 60 mcg/mealAs given in this study (human).

    Measurements

    Patients with hypoglycemia
    6 patients
    type 1 diabetes patients during the study

    Source sentences

    Summary
    Hypoglycemia occurred in 6 patients during the study; the assistance of another person was not required in any of these cases.
    3 context sentences
    Summary · context
    In this prospective study, insulin pump-treated patients with type 1 diabetes had insulin dosages optimally titrated on the basis of daily continuous glucose monitoring (CGM).
    Summary · context
    Pramlintide therapy was initiated, and the dosage was increased 15 mcg/meal per week.
    Summary · context
    Within 2 weeks of achieving a pramlintide dosage of 60 mcg/meal, the second CGM-guided insulin dosage adjustment was done.
  2. 02HumanNon-randomized trialSafety outcome

    In patients with type 1 diabetes, no hypoglycemia was reported during the first week of pramlintide.

    In plain wordsIn patients with type 1 diabetes, no low blood sugar was reported during the first week of pramlintide.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableFirst-week hypoglycemia
    Study

    n = 9

    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Titrated to 60 mcg/mealAs given in this study (human).

    Source sentences

    Summary
    No hypoglycemia was reported in the first week of starting pramlintide.
    3 context sentences
    Summary · context
    In this prospective study, insulin pump-treated patients with type 1 diabetes had insulin dosages optimally titrated on the basis of daily continuous glucose monitoring (CGM).
    Summary · context
    Pramlintide therapy was initiated, and the dosage was increased 15 mcg/meal per week.
    Summary · context
    Within 2 weeks of achieving a pramlintide dosage of 60 mcg/meal, the second CGM-guided insulin dosage adjustment was done.
  3. 03HumanNon-randomized trialSafety outcome

    In patients with type 1 diabetes, 6 patients reported mild to moderate nausea during pramlintide titration.

    In plain wordsIn patients with type 1 diabetes, 6 patients reported mild to moderate nausea during dose increases.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableNausea
    Study

    n = 9

    Analysis
    Secondary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Titrated to 60 mcg/mealAs given in this study (human).

    Measurements

    Patients with mild to moderate nausea
    6 patients
    type 1 diabetes patients during the titration phase

    Source sentences

    Summary
    Mild to moderate nausea was reported in 6 patients during the titration phase.
    3 context sentences
    Summary · context
    In this prospective study, insulin pump-treated patients with type 1 diabetes had insulin dosages optimally titrated on the basis of daily continuous glucose monitoring (CGM).
    Summary · context
    Pramlintide therapy was initiated, and the dosage was increased 15 mcg/meal per week.
    Summary · context
    Within 2 weeks of achieving a pramlintide dosage of 60 mcg/meal, the second CGM-guided insulin dosage adjustment was done.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with type 1 diabetes, pramlintide reduced weight.

    In plain wordsIn patients with type 1 diabetes, weight decreased during pramlintide treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseWeight
    Study

    n = 9

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Titrated to 60 mcg/mealAs given in this study (human).

    Source sentences

    Summary
    Pramlintide was well tolerated and resulted in decrease in weight and hemoglobin A1c values.
    3 context sentences
    Summary · context
    In this prospective study, insulin pump-treated patients with type 1 diabetes had insulin dosages optimally titrated on the basis of daily continuous glucose monitoring (CGM).
    Summary · context
    Pramlintide therapy was initiated, and the dosage was increased 15 mcg/meal per week.
    Summary · context
    Within 2 weeks of achieving a pramlintide dosage of 60 mcg/meal, the second CGM-guided insulin dosage adjustment was done.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with type 1 diabetes, pramlintide reduced hemoglobin A1c.

    In plain wordsIn patients with type 1 diabetes, hemoglobin A1c decreased during pramlintide treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseHemoglobin A1c
    Study

    n = 9

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Titrated to 60 mcg/mealAs given in this study (human).

    Source sentences

    Summary
    Pramlintide was well tolerated and resulted in decrease in weight and hemoglobin A1c values.
    3 context sentences
    Summary · context
    In this prospective study, insulin pump-treated patients with type 1 diabetes had insulin dosages optimally titrated on the basis of daily continuous glucose monitoring (CGM).
    Summary · context
    Pramlintide therapy was initiated, and the dosage was increased 15 mcg/meal per week.
    Summary · context
    Within 2 weeks of achieving a pramlintide dosage of 60 mcg/meal, the second CGM-guided insulin dosage adjustment was done.
  6. 06HumanNon-randomized trialSafety outcome

    In patients with type 1 diabetes, pramlintide was well tolerated.

    In plain wordsIn patients with type 1 diabetes, pramlintide was well tolerated.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableTolerability
    Study

    n = 9

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Titrated to 60 mcg/mealAs given in this study (human).

    Source sentences

    Summary
    Pramlintide was well tolerated and resulted in decrease in weight and hemoglobin A1c values.
    3 context sentences
    Summary · context
    In this prospective study, insulin pump-treated patients with type 1 diabetes had insulin dosages optimally titrated on the basis of daily continuous glucose monitoring (CGM).
    Summary · context
    Pramlintide therapy was initiated, and the dosage was increased 15 mcg/meal per week.
    Summary · context
    Within 2 weeks of achieving a pramlintide dosage of 60 mcg/meal, the second CGM-guided insulin dosage adjustment was done.

Studies that did not test the peptide alone2

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 07HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialEfficacy outcome

    In pump-treated patients with type 1 diabetes, CGM-guided insulin adjustment reduced total basal insulin dosage.

    In plain wordsIn patients with type 1 diabetes, glucose-monitor-guided adjustment reduced basal insulin dosage from baseline.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseTotal basal insulin dosage
    Study

    n = 9

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Basal insulin dosage change
    −11.2%
    CGM-guided adjustment

    Source sentences

    Summary
    The difference between before and during CGM-guided insulin dosing was a mean (+/- standard deviation) TBD change of -11.2 +/- 13.2% (P = 0.023) and mean ICR change of 7.8 +/- 13.4% (P = 0.053).
    3 context sentences
    Summary · context
    In this prospective study, insulin pump-treated patients with type 1 diabetes had insulin dosages optimally titrated on the basis of daily continuous glucose monitoring (CGM).
    Summary · context
    Pramlintide therapy was initiated, and the dosage was increased 15 mcg/meal per week.
    Summary · context
    Within 2 weeks of achieving a pramlintide dosage of 60 mcg/meal, the second CGM-guided insulin dosage adjustment was done.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 08HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialEfficacy outcome

    In pump-treated patients with type 1 diabetes, the insulin to carbohydrate ratio change was not significant during CGM-guided adjustment.

    In plain wordsIn patients with type 1 diabetes, the insulin to carbohydrate ratio did not change significantly from baseline.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeInsulin to carbohydrate ratio
    Study

    n = 9

    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Insulin to carbohydrate ratio change
    7.8%
    CGM-guided adjustment

    Source sentences

    Summary
    The difference between before and during CGM-guided insulin dosing was a mean (+/- standard deviation) TBD change of -11.2 +/- 13.2% (P = 0.023) and mean ICR change of 7.8 +/- 13.4% (P = 0.053).
    3 context sentences
    Summary · context
    In this prospective study, insulin pump-treated patients with type 1 diabetes had insulin dosages optimally titrated on the basis of daily continuous glucose monitoring (CGM).
    Summary · context
    Pramlintide therapy was initiated, and the dosage was increased 15 mcg/meal per week.
    Summary · context
    Within 2 weeks of achieving a pramlintide dosage of 60 mcg/meal, the second CGM-guided insulin dosage adjustment was done.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.